	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	569	631	733	857	1,008	1,097	1,042	968	1,107	1,242	1,541	1,669	1,817	1,665	1,845
Cost of Operating Revenue	287	307	327	375	440	481	455	433	448	480	600	661	730	678	668
Gross Profit	282	324	406	482	568	616	587	535	659	761	941	1,008	1,087	987	1,177
Gross Margin	49.5	51.3	55.4	56.3	56.3	56.2	56.3	55.3	59.5	61.3	61.1	60.4	59.8	59.3	63.8
Total Operating Expenses	503	562	643	739	893	1,003	975	963	1,051	1,090	1,290	1,452	1,664	1,679	1,830
Operating Profit	65	69	90	118	115	94	67	6	56	151	251	217	153	-14	15
Operating Margin	11.5	10.9	12.2	13.8	11.4	8.5	6.5	0.6	5.0	12.2	16.3	13.0	8.4	-0.8	0.8
Financing Income/(Expense) - Net	-15	-21	-18	-10	-12	-3	-21	-19	-25	-21	-14	-24	-34	-65	-122
Profit before Taxes	51	49	72	110	99	91	48	-9	29	132	237	193	136	-74	-107
Income Taxes	5	6	14	27	17	14	7	-6	4	39	82	51	39	4	-8
Profit after Tax	46	43	58	83	82	77	41	-3	24	93	155	142	98	-74	-95
PAT Margin	8.1	6.8	7.9	9.7	8.1	7.0	4.0	-0.3	2.2	7.5	10.0	8.5	5.4	-4.4	-5.2
EPS - Basic - ex Extraordinary Items	5.03	4.64	6.29	8.99	8.89	8.36	4.47	-0.32	2.62	10.10	16.80	15.44	10.68	-8.00	-10.70
EPS - Diluted - ex Extraordinary Items	5.03	4.64	6.29	8.99	8.89	8.36	4.47	-0.32	2.62	10.10	16.80	15.42	10.67	-8.00	-10.70
EBIT	65	69	90	118	115	94	67	6	56	151	251	217	153	-14	15
EBITDA	85	93	120	166	175	157	135	77	123	225	328	288	245	100	142
EBITDA Margin	14.9	14.7	16.4	19.3	17.4	14.3	13.0	8.0	11.2	18.1	21.3	17.2	13.5	6.0	7.7

Balance Sheet

Abridged

Understanding Balance Sheet

Indoco Remedies Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	264	276	305	389	465	572	539	538	563	623	774	814	955	1,001	1,193
Long-Term Investments	0	0	0	4	5	0	0	0	0	0	0	1	1	1	15
Property Plant & Equipment - Net	300	313	320	320	340	433	517	558	549	554	585	668	891	1,125	1,082
Total Non-Current Assets	392	416	425	431	476	625	699	720	708	693	712	845	1,190	1,429	1,400
Total Assets	656	692	729	820	941	1,197	1,238	1,258	1,272	1,315	1,486	1,658	2,145	2,430	2,593
Total Current Liabilities	182	199	202	258	303	390	417	446	459	407	425	425	612	808	1,053
Long Term Debt	47	27	14	13	38	132	123	129	102	104	107	159	364	543	558
Total Non-Current Liabilities	90	78	70	34	61	155	146	152	133	139	157	205	422	604	609
Total Liabilities	272	277	272	293	364	545	563	597	592	546	581	630	1,034	1,412	1,661
Total Shareholders' Equity	385	414	457	528	577	651	675	661	680	769	905	1,028	1,110	1,022	939
Minority Interest	-	0	0	0	0	0	0	-	-	-	-	-	1	-4	-7
Total Equity	385	414	457	528	577	651	675	661	680	769	905	1,028	1,110	1,018	932
Total Liabilities & Equity	656	692	729	820	941	1,197	1,238	1,258	1,272	1,315	1,486	1,658	2,145	2,430	2,593

Cash Flow

Abridged

Understanding Cash Flow Statement

Indoco Remedies Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	C 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	65.25	71.71	88.72	136.63	138.20	120.64	119.75	57.17	103.14	199.54	267.99	225.28	212.19	29.08	15.26
Working Capital - Increase/(Decrease)	-10.03	-18.57	-9.16	-41.01	-38.46	-43.25	-13.23	55.62	-1.49	-139.81	-108.78	-73.18	-88.47	2.78	55.64
Net CF from Operating Activities	55.21	53.13	79.56	95.63	99.74	77.39	106.52	112.79	101.65	59.72	159.20	152.10	123.72	31.86	70.90
Capital Expenditures - Net	65.51	43.11	41.50	88.68	97.35	188.86	137.26	93.00	58.36	76.65	124.39	206.09	424.31	352.36	100.89
Net CF from Investing Activities	-65.61	-43.11	-41.55	-88.88	-111.21	-172.44	-138.26	-105.25	-57.07	-67.40	-121.78	-208.64	-436.98	-339.96	-102.98
Dividends Paid - Cash - Total	11.42	11.74	11.85	15.08	32.99	2.42	17.73	11.09	3.36	2.79	13.79	20.72	20.71	13.90	1.91
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	-	-	-	0.77	1.59	1.30
Debt - LT & ST - Issuance/(Retirement) - Total	9.58	3.39	-27.30	9.03	44.35	147.14	-2.01	15.77	-38.25	-3.88	-15.59	70.72	336.50	317.65	46.86
Net Cash Flow from Financing Activities	-1.84	-8.35	-39.16	-6.05	11.36	144.71	-19.74	4.68	-41.62	-6.67	-29.38	50.00	316.57	305.34	45.90
Free Cash Flow to Equity	-0.72	13.42	10.75	15.98	46.74	35.67	-32.75	35.56	5.03	-20.80	19.23	16.74	35.91	-2.85	16.87
Free Operating CF net dividend	-22.18	-1.97	25.94	-8.19	-30.96	-114.60	-50.66	4.75	39.82	-19.91	20.09	-75.87	-322.98	-338.19	-78.54
Free Operating CF	-10.76	9.77	37.79	6.89	2.04	-112.18	-32.92	15.84	43.19	-17.12	33.88	-55.15	-302.28	-324.29	-76.63

Business Segment Analysis

FY End:

Mar 25

Indoco Remedies Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 356.15 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 1,664.92 Cr

Assets

Pharmaceuticals (100.0%)₹ 2,429.91 Cr

Operating Income

Pharmaceuticals (100.0%)₹ -13.85 Cr

Regional Segment Analysis

FY End:

Mar 25

Indoco Remedies Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (66.4%)₹ 1,090.39 CrOutside India. (33.6%)₹ 550.90 Cr

Historical Segment Analysis

Track how Indoco Remedies Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	58	77	125	207	427	356

Frequently Asked Questions

What is the revenue of Indoco Remedies Ltd.?

The latest trailing twelve month revenue of Indoco Remedies Ltd. is ₹ 1,845.32 Cr, reflecting a 1-year growth of 10.84% and a 3-year CAGR of 3.41%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Indoco Remedies Ltd.?

The latest trailing twelve month net profit (PAT) of Indoco Remedies Ltd. is ₹ -95.15 Cr, with a 3-year earnings CAGR of -39.14%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Indoco Remedies Ltd.?

The trailing twelve month EBITDA of Indoco Remedies Ltd. is approximately ₹ 15.35 Cr (based on an operating margin of 0.83%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Indoco Remedies Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Indoco Remedies Ltd. is -10.70. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Indoco Remedies Ltd.?

The debt-to-equity ratio of Indoco Remedies Ltd. stands at 1.16. The interest coverage ratio is 0.13x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Indoco Remedies Ltd.?

The estimated book value per share of Indoco Remedies Ltd. is 101.85 (derived from a P/B ratio of 2.43 and market price of ₹ 247.45), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Indoco Remedies Ltd.?

The trailing twelve month operating cash flow of Indoco Remedies Ltd. is ₹ 70.90 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Indoco Remedies Ltd. report consolidated or standalone financials?

Indoco Remedies Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.